Atea Pharmaceuticals (AVIR) Enterprise Value (2019 - 2026)

Atea Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$256.0 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 39.83% year-over-year to -$256.0 million in Q1 2026; TTM through Mar 2026 was -$256.0 million, a 39.83% increase from a year earlier, with the FY2025 full-year figure at -$301.8 million, up 64.11% from the prior year.
• Enterprise Value grew to -$256.0 million in Q1 2026 per AVIR's latest filing, from -$301.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$256.0 million in Q1 2026 and bottomed at -$919.8 million in Q1 2024.
• The 5-year median for Enterprise Value is -$620.5 million (2023), against an average of -$592.6 million.
• Across the five-year window, Enterprise Value slumped 48.23% in 2024 and surged 64.11% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$646.7 million in 2022, then climbed by 10.61% to -$578.1 million in 2023, then tumbled by 45.48% to -$841.0 million in 2024, then soared by 64.11% to -$301.8 million in 2025, then rose by 15.18% to -$256.0 million in 2026.
• Per Business Quant, the three latest AVIR Enterprise Value figures stand at -$256.0 million (Q1 2026), -$301.8 million (Q4 2025), and -$329.3 million (Q3 2025).